Schonfeld Strategic Advisors LLC Has $21.37 Million Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)

Schonfeld Strategic Advisors LLC lifted its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 57.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,789,379 shares of the company's stock after acquiring an additional 1,382,176 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 4.48% of Verve Therapeutics worth $21,372,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of Verve Therapeutics by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,625,780 shares of the company's stock valued at $9,172,000 after purchasing an additional 25,093 shares in the last quarter. Northern Trust Corp grew its holdings in Verve Therapeutics by 12.7% during the 4th quarter. Northern Trust Corp now owns 650,562 shares of the company's stock worth $3,669,000 after acquiring an additional 73,295 shares during the last quarter. Trexquant Investment LP increased its position in Verve Therapeutics by 14.5% in the 4th quarter. Trexquant Investment LP now owns 635,847 shares of the company's stock valued at $3,586,000 after acquiring an additional 80,345 shares during the period. Dimensional Fund Advisors LP increased its position in Verve Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 437,089 shares of the company's stock valued at $2,465,000 after acquiring an additional 5,320 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in shares of Verve Therapeutics by 4.2% during the fourth quarter. Wellington Management Group LLP now owns 361,498 shares of the company's stock worth $2,039,000 after purchasing an additional 14,469 shares during the period. Institutional investors own 97.11% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on VERV. Royal Bank of Canada lowered their target price on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. HC Wainwright raised their price objective on Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, April 14th. Cantor Fitzgerald upgraded Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th. William Blair restated an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. Finally, Guggenheim upped their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $25.75.

Verve Therapeutics Trading Down 1.4 %

VERV stock traded down $0.08 during mid-day trading on Monday, reaching $5.12. The company's stock had a trading volume of 843,054 shares, compared to its average volume of 1,785,240. Verve Therapeutics, Inc. has a 12 month low of $2.86 and a 12 month high of $9.31. The business's 50 day moving average price is $5.16 and its 200 day moving average price is $5.96. The company has a market cap of $455.97 million, a price-to-earnings ratio of -2.08 and a beta of 1.86.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.14. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. As a group, equities analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.